NSIM
ATOS icon

North Star Investment Management’s Atossa Therapeutics ATOS Stock Holding History

North Star Investment Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-80
Closed -$421 – 1741
2026
Q1 		$421 Buy
+80
New +$507 ﹤0.01% 1648

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

North Star Investment Management's ATOS Position: Q2 2026 in Review

North Star Investment Management sold out of Atossa Therapeutics (ATOS) in Q2 2026, closing a stake of 80 shares — an estimated $421 sold.

North Star Investment Management first reported a position in ATOS in Q1 2026 and held it in 1 quarter. The position peaked at $421 in Q1 2026. 31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • North Star Investment Management reported no remaining Atossa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • North Star Investment Management sold 80 Atossa Therapeutics shares in Q2 2026, an estimated $421.
  • North Star Investment Management first reported a position in Atossa Therapeutics in Q1 2026 and held it in 1 quarter.
  • North Star Investment Management's Atossa Therapeutics position peaked at $421 in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on North Star Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.